{
    "organizations": [],
    "uuid": "d3ccd95834c378de0832a8c8215d28afb0140edf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biofrontera-12-month-follow-up-res/brief-biofrontera-12-month-follow-up-results-of-phase-iii-trial-for-daylight-pdt-idUSFWN1PI178",
    "ord_in_thread": 0,
    "title": "BRIEF-Biofrontera: 12-Month Follow-Up Results Of Phase III Trial For Daylight PDT",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 23 (Reuters) - BIOFRONTERA AG:\n* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES 12-MONTH FOLLOW-UP RESULTS OF THE PHASE III TRIAL FOR DAYLIGHT PDT\n* OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS A CLEAR TREND TOWARDS IMPROVED EFFICACY\n* OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS LOWER RECURRENCE RATES FOR AMELUZ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-24T01:22:00.000+02:00",
    "crawled": "2018-01-24T15:30:31.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "biofrontera",
        "ag",
        "biofrontera",
        "ag",
        "biofrontera",
        "receives",
        "result",
        "phase",
        "iii",
        "trial",
        "daylight",
        "pdt",
        "overall",
        "comparison",
        "ameluz",
        "metvix",
        "show",
        "clear",
        "trend",
        "towards",
        "improved",
        "efficacy",
        "overall",
        "comparison",
        "ameluz",
        "metvix",
        "show",
        "lower",
        "recurrence",
        "rate",
        "ameluz",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}